

AGIOS PHARMACEUTICALS INC  
Form DEFA14A  
June 16, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14A**

**(Rule 14a-101)**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**

**(Amendment No.    )**

Filed by the Registrant       Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

Definitive Proxy Statement

Definitive Additional Materials

.. Soliciting Material under § 240.14a-12

**Agios Pharmaceuticals, Inc.**

**(Name of Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

No fee required.

.. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

.. Fee paid previously with preliminary materials.

.. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

88 Sidney Street, Cambridge, Massachusetts 02139

June 16, 2016

**Supplement to Definitive Proxy Statement Relating to 2016 Annual Meeting of Stockholders**

This proxy statement supplement, dated June 16, 2016, supplements the definitive proxy statement (the Proxy Statement) of Agios Pharmaceuticals, Inc. (the Company) filed with the Securities and Exchange Commission on April 27, 2016 relating to the Annual Meeting of Stockholders of the Company to be held on June 21, 2016 beginning at 9:00 a.m., Eastern Time, at the Company's offices at 88 Sidney Street, Cambridge, Massachusetts 02139.

The purpose of this supplement is to correct an error in the Director Compensation Table included at page 28 of the Proxy Statement. The table inadvertently contained overstated amounts in the Option Awards (\$) column. The corrected table is included below. The footnotes to the table did not change, were unaffected by the overstatement, and are not repeated in this supplement.

| Name                        | Fees Earned or Option Awards |                 |              | Number of Shares Subject to Options Awards Held as of December 31, 2015 |
|-----------------------------|------------------------------|-----------------|--------------|---|
|                             | Paid in Cash (\$)            | (\$)(1)         | Total (\$)   |   |
| Lewis C. Cantley, Ph.D.     | \$ 40,000                    | \$ 637,911(2)   | \$ 677,911   | 168,579   |
| Paul J. Clancy              | \$ 50,000                    | \$ 714,461(3)   | \$ 764,461   | 49,400  |
| Douglas G. Cole, M.D.       | \$ 46,000                    | \$ 637,911(2)   | \$ 683,911   | 23,125  |
| Kaye Foster                 | \$ 46,000                    | \$ 714,401(4)   | \$ 760,401   | 36,899  |
| Maykin Ho, Ph.D.            | \$ 28,000                    | \$ 1,374,682(5) | \$ 1,402,682 | 21,250  |
| Perry Karsen(6)             | \$ 35,000                    | \$ 637,911(2)   | \$ 672,911   | 10,625  |
| John M. Maraganore, Ph.D.   | \$ 47,500                    | \$ 637,911(2)   | \$ 685,411   | 33,125  |
| Robert T. Nelsen            | \$ 40,000                    | \$ 637,911(2)   | \$ 677,911   | 23,125  |
| Kevin Starr (7)             | \$ 32,250                    |                 | \$ 32,250    |   |
| Marc Tessier-Lavigne, Ph.D. | \$ 72,500                    | \$ 676,156(8)   | \$ 748,656   | 40,375  |

Except as specifically supplemented by the information contained herein, all information set forth in the Proxy Statement remains unchanged.